Cortisol Synthesis Inhibitor Drug Class List

Drugs in Drug Class: Cortisol Synthesis Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes

Last updated: July 17, 2026

Market Dynamics and Patent Landscape for Cortisol Synthesis Inhibitor Drugs (R&D, Licensing, and Generic Entry Risk)

Cortisol synthesis inhibitor is a label for a small but fast-moving therapeutic niche centered on steroidogenesis blockade, most visibly exemplified by metyrapone and ketoconazole derivatives, and increasingly by precision inhibitors of adrenal enzymes (11β-hydroxylase and related nodes in cortisol biosynthesis). Patent estates in this class are typically fragmented across active ingredients, formulation/manufacturing, and method-of-treatment claims. Market dynamics are shaped by (1) tight clinical positioning in adrenal disorders and (2) regulatory and safety constraints that narrow the number of viable competitors and increase the leverage of late-cycle formulation and dosing patents.

What follows is a practical view of the patent-and-market structure common to cortisol synthesis inhibitor drugs: where exclusivity comes from, what breaks first, what Paragraph IV and biosimilar-equivalent challenges look like in practice, and where generic entry is most likely to be blocked.

---

Which drugs are considered cortisol synthesis inhibitors in practice?

Featured snippet: Cortisol synthesis inhibitors are steroidogenesis blockers that reduce adrenal cortisol production by inhibiting key enzymes in the cortisol biosynthetic pathway.

What enzyme targets define the class?

Common target nodes in cortisol biosynthesis include:

• CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone synthase) in the adrenal cortex
• Steroidogenic enzymes upstream of cortisol, including 17α-hydroxylation steps
• Non-selective steroidogenesis inhibition as seen in older agents (historically ketone/hydroxylation-related chemistry)

Which marketed actives anchor the category?

Across major markets, the category is anchored by:

• Metyrapone (classic 11β-hydroxylation inhibitor)
• Ketoconazole (broad CYP steroidogenic inhibition; off-label use is common even when primary indications differ)

The class also contains more modern, potentially more selective enzyme inhibitors in development and some markets, though the exact competitive set depends on geography and indication.

---

What patents protect cortisol synthesis inhibitors? (API, formulations, methods)

Featured snippet: Patent protection typically splits into four buckets: compound (composition of matter), process/manufacturing, formulations (solid state/dosage), and method-of-use for specific indications and dosing regimens.

How strong is compound IP in this class?

Strength varies by generation:

• Older molecules (e.g., metyrapone-era chemistry) tend to have older, narrower compound families with limited remaining exclusivity in many jurisdictions.
• Newer development programs tend to focus on enzyme selectivity improvements, stereochemistry, salts/co-crystals, and solid-state forms plus controlled dosing claims.

What formulation patents matter most?

In cortisol synthesis inhibitor drugs, formulation patents usually cover:

• Particle size distributions and milling/processing parameters to control dissolution and bioavailability
• Solid-state form (polymorph, hydrate, solvate) for oral tablets/capsules
• Co-administration regimens (timing, food effects) and exposure targets that support method-of-treatment claims
• Manufacturing process controls that establish reproducible release and stability

What method-of-use claims drive late-cycle exclusivity?

Method patents frequently map to:

• Treatment of specific cortisol-related indications (adrenal hypercortisolism, Cushing’s syndrome variants, congenital adrenal hyperplasia-related cortisol dysregulation where applicable)
• Specific dosing titration schedules and monitoring strategies (e.g., cortisol level targets, ACTH response handling)
• Combination regimens with glucocorticoid replacement and mitigation of adrenal insufficiency risk

---

When does exclusivity end for cortisol synthesis inhibitor drugs? (timing framework)

Featured snippet: Exclusivity ends in layers: patent term first (composition/process), then any pediatric extensions, then regulatory exclusivity (if applicable), then generic launch windows tied to Orange Book or foreign equivalents.

Key exclusivity timeline mechanics

For each marketed product in this class, exclusivity sequencing typically looks like:

1. Composition of matter and key intermediate/process patents begin expiring first on an international schedule
2. Pediatric exclusivity (if granted) can extend patent term in the US by up to 6 months for qualifying patents
3. Orphan drug and other regulatory exclusivities can add time but are indication-dependent
4. Method-of-use patents can remain after compound expiry and still block “use” carveouts even if the API goes generic

Practical implication for investors and licensing teams

In cortisol synthesis inhibitors, method-of-use patents can keep branded therapy protected even when the active ingredient is accessible. That shifts licensing leverage from “generic API entry” to “generic label and regimen design.”

---

Which patents block generic entry for cortisol synthesis inhibitors? (Paragraph IV and use carveouts)

Featured snippet: Generic entry is usually blocked by (a) still-in-force method-of-use patents and (b) formulation/process patents that define controlled release or exposure behavior, not by the basic API alone.

Paragraph IV realities in this class

For small molecule cortisol synthesis inhibitors, the most common barriers to Paragraph IV approval and non-infringement are:

• Method-of-treatment claims that align with the generic’s proposed indication and dosing titration
• Formulation and manufacturing claims for specific solid-state forms or stability-controlled processes
• Combination regimen patents that govern co-therapy and sequencing

What does “labeling design” do in practice?

If a branded product faces method-of-use protection, generic sponsors often try:

• To carve out protected indications or dosing regimens
• To propose labeling that avoids direct infringement, depending on claim language and enforcement patterns
• To rely on non-infringing formulations that change dissolution, bioavailability, or release profiles

In steroidogenesis inhibitor drug families, claim language often targets dosing schedules tied to biochemical targets, which makes label carveouts harder than for broader symptom indications.

---

What is the Orange Book status of cortisol synthesis inhibitor drugs?

Featured snippet: US exclusivity is reflected through listed patents in the Orange Book, covering active ingredient, formulation, and method-of-use for the approved NDA label.

How to interpret Orange Book listings in this niche

In cortisol synthesis inhibitor drugs, Orange Book entries often show:

• Multiple listed patents per product covering formulation and method-of-use
• Last-to-expire patents that are not the compound patents but rather method or formulation families

What investors should screen first

• The latest expiring listed patent numbers tied to formulation and method-of-use
• Whether there are “multiple listed patents” with similar expiration dates, signaling a dense claim estate
• Whether any patents are delisted or amended post-grant, affecting Paragraph IV risk

---

How does the patent estate for metyrapone compare with ketoconazole-based steroidogenesis inhibition?

Featured snippet: Older steroidogenesis inhibitors often have less remaining compound exclusivity, while modern patent estates, where present, concentrate in method-of-use and formulation.

Metyrapone-style estates

Typical characteristics of older adrenal enzyme inhibitors:

• Compound families frequently expired or close to expiry in major jurisdictions
• Remaining protection often sits in formulation/process improvements and specific dosing and monitoring protocols

Ketoconazole-style positioning

Ketoconazole has a long history and broader steroid enzyme inhibition profile:

• Patent estates may be tied to specific formulations and dosing regimens
• Clinical use across multiple indications can lead to method-of-use claim blocks even after API access

Competitive consequence

Even if API patent expiry occurs, label-driven method patents can keep branded dosing patterns protected. This favors branded manufacturers in payer negotiations where treatment protocols are codified.

---

What formulation patents are protected in cortisol synthesis inhibitor drugs?

Featured snippet: Formulation protection is often the most durable IP lever after composition-of-matter expiry, especially for solid-state forms and exposure-control.

Solid-state and manufacturing claim clusters

Common protected elements include:

• Polymorph/hydrate/solvate specifications that improve stability
• Compression and granulation parameters affecting dissolution rate
• Stability-controlled manufacturing steps and packaging requirements
• Bioequivalence-preserving changes that generic firms may fail to replicate without infringing

Why this matters for generic development

Steroidogenesis inhibitors can show:

• Narrow therapeutic windows in practice due to cortisol suppression and adrenal insufficiency risk
• Strong sensitivity of exposure-response relationships to bioavailability differences

That drives enforcement focus toward formulation and method claims that control effective cortisol lowering and safety outcomes.

---

Which method-of-use patents are likely to matter in cortisol synthesis inhibitor enforcement?

Featured snippet: Method-of-use patents that specify indication, dosing titration, monitoring, and steroid replacement schedules are the hardest for generic sponsors to avoid.

Enforcement-relevant claim themes

Method claims often target:

• Use for adrenal hypercortisolism or related cortisol excess states
• Dosing titration to maintain cortisol within a defined biochemical range
• Monitoring protocols for ACTH and cortisol and response adaptation
• Co-therapy requirements to reduce risk of adrenal insufficiency

Labeling and infringement risk

Generic sponsors face higher risk when:

• The proposed labeling includes titration and monitoring language parallel to the branded patent specification
• The dose is tied to biochemical targets in a way that maps to claim limitations

---

What litigation and settlements affect cortisol synthesis inhibitor competition?

Featured snippet: Litigation risk in this class is driven by late-listed method-of-use and formulation patents rather than early compound claims.

Common settlement patterns in small-molecule steroid inhibitor categories

Settlements often reflect:

• Carve-out labeling for protected indications or regimens
• Entry at a later date aligned with the last-to-expire formulation/method patent
• Cross-licensing of specific formulation approaches to enable “design-around” entry

Where litigation concentrates

In cortisol synthesis inhibitor drugs, litigation concentrates in:

• US Hatch-Waxman Paragraph IV cases on Orange Book-listed patents
• International counterparts where formulation patents are enforceable and have long remaining terms
• Enforcement of method claims when generic labeling matches the branded clinical protocol

---

What generic entry risks exist for cortisol synthesis inhibitors?

Featured snippet: Generic risk is highest when compound patents expire early and the remaining listed patents are primarily formulation or method-of-use that can be avoided by label carveouts or non-infringing formulations.

Risk drivers for branded incumbents

• Dense method-of-use listing increases blocking power but also narrows the feasible generic label
• If generic sponsors can propose a different dosing regimen and monitoring protocol, they can reduce infringement exposure

Risk drivers for generics

• Formulation complexity and stability requirements increase development time
• Bioavailability variability can lead to failed bioequivalence and rework, raising launch timelines

---

How does pathway choice (NDA vs 505(b)(2) vs ANDA) change patent exposure?

Featured snippet: 505(b)(2) can shift patent exposure and data requirements, but it does not eliminate infringement risk for method and formulation patents.

Generic development pathways

• ANDA: requires bioequivalence to the reference listed drug and faces the most direct Orange Book patent confrontation via Paragraph IV or Paragraph III certifications
• 505(b)(2): can leverage published data and bridge studies; still triggers patent certifications if relying on an RLD
• Switch from one formulation to another: can avoid some formulation claims but may still collide with method-of-use patents on dosing and indications

Competitive consequence

In cortisol synthesis inhibitor markets, pathway strategy often targets label and regimen design to reduce method claim alignment.

---

How does biosimilar risk apply to cortisol synthesis inhibitors?

Featured snippet: Biosimilar risk is not a relevant primary threat because cortisol synthesis inhibitors in this class are generally small-molecule drugs, not biologics.

Practical implication

The main threat vector is ANDA small-molecule generic entry, not biosimilar substitution.

---

What commercial metrics and market dynamics shape pricing and entry?

Featured snippet: In cortisol synthesis inhibitors, commercialization depends more on clinical protocol fit, monitoring infrastructure, and payer coverage than on broad primary-care adoption.

Key market dynamics

• Treatment is specialized, with high dependence on endocrinology and adrenal disease centers
• Payers focus on safety outcomes and protocol adherence due to cortisol suppression and adrenal insufficiency risk
• Branded advantage can persist if method-of-use claims map to standard-of-care monitoring and titration

Competitive pricing dynamics

• When generic entry occurs, price compression is likely fastest in markets where method-of-use barriers are overcome via labeling carveouts
• In cases where method claims remain enforced, branded pricing can hold longer because generics may not be able to fully replicate the label-based treatment protocol

---

Which companies are positioned to compete in cortisol synthesis inhibitor markets?

Featured snippet: Competition comes from (1) branded originators with dense method/formulation estates and (2) generic sponsors targeting label carveouts or non-infringing formulations.

Competitive landscape assessment approach

A business team should screen:

• Orange Book density: number of listed patents and last-to-expire family
• Litigation history: prior Paragraph IV challenges in the same product family
• Formulation complexity: evidence of difficulty in bioequivalence or stability
• Geographic coverage: where patents are enforceable and where generic approvals are likely

---

Key Takeaways

• Cortisol synthesis inhibitors are typically protected by layered IP: compound plus a larger share of method-of-use and formulation patents that can outlast API exclusivity.
• Generic entry risk is primarily controlled by Orange Book-listed method and formulation patents, not by compound expiry alone.
• Where method claims tightly map to dosing titration and monitoring protocols, generic sponsors face higher label design constraints and later market entry.
• Market dynamics favor incumbents when clinical protocols are standardized and method-of-use patents align with label language.
• Biosimilar risk is not the main competitive threat in this class; ANDA and 505(b)(2) small-molecule strategies drive competition.

---

FAQs

1) What patent types tend to remain “last-to-expire” for cortisol synthesis inhibitors?

Method-of-use and formulation patents commonly remain after composition-of-matter families expire, especially where claims specify dosing titration and monitoring to achieve biochemical cortisol targets.

2) Can generics launch without infringing cortisol suppression method-of-use claims?

Only if the generic’s proposed label and regimen avoid claim limitations. If dosing titration and monitoring language aligns with the branded claims, infringement risk remains high.

3) How do formulation patents affect ANDA bioequivalence strategy?

They can limit design-around options by controlling solid-state form, dissolution behavior, and manufacturing parameters that influence exposure-response and safety outcomes.

4) What settlement terms are typical in Orange Book fights for steroidogenesis inhibitors?

Common terms include date-based entry triggers aligned to last-to-expire patents and label carveouts that avoid protected indications or dosing regimens.

5) What is the most reliable signal to predict generic launch timing?

The last-to-expire Orange Book-listed patent family tied to method-of-use and formulation, combined with observed litigation and settlement patterns, is the strongest practical timing indicator.

---

References

No sources were cited in the provided content.